A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma (LEBEN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01412307|
Recruitment Status : Unknown
Verified August 2015 by Antonio Pinto, Fondazione Giovanni Pascale.
Recruitment status was: Active, not recruiting
First Posted : August 9, 2011
Last Update Posted : August 11, 2015
Management of patients with recurring Hodgkin lymphoma (HL) after stem cell transplantation failure represents a typical unmet medical need prompting active development and validation of new agents and treatment strategies. The LEBEN protocol combines two agents, lenalidomide and bendamustine, framing different targets on both tumor and microenvironmental cells of HL. These agents, while showing a low risk of overlapping extrahematologic toxicities, may hit the proliferation machinery of H-RS cells and/or their progenitors, synergistically inhibit tumor-related angiogenesis and interfere on cytokine-mediate circuitries operating in the microenvironment to support tumor cell survival.
A weekly schedule of bendamustine, at 60 mg/m2, is combined with the continuous administration of increasing dose of lenalidomide (10, 15, 20 e 25 mg dose levels in a 28-day cycle). Such schedule of Bendamustine is aimed at enhancing the antiangiogenic and immunomodulatory activity of continuous Lenalidomide, as studies have shown that low and protracted doses of alkylators induce a decrease in microvascular density of tumor tissues and inhibit mobilization and viability of circulating endothelial progenitors.
The Bayesian phase 1/2 dose finding method of Thall and Cook was employed. This method chooses doses based-on both response and toxicity, and accounts for the trade-off between these two outcomes.
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Adult Hodgkin Lymphoma||Drug: Lenalidomide Drug: Bendamustine Other: Bio-specimen Retention||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||36 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine (LEBEN) in Relapsed and Primary Refractory Hodgkin Lymphoma|
|Study Start Date :||July 2011|
|Actual Primary Completion Date :||July 2015|
|Estimated Study Completion Date :||July 2016|
U.S. FDA Resources
|Experimental: lenalidomide plus bendamustine||
10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
Other Names:Drug: Bendamustine
intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
Other Names:Other: Bio-specimen Retention
Samples with DNA and without DNA
- Dose finding, as best trade-off between toxicity and efficacy according to the Bayesian phase I/II dose finding method of Thall and Cook [ Time Frame: Evaluation at day +56, i.g. after two cycles. ]According to the Bayesian phase I/II dose finding method of Thall and Cook,a target efficacy-toxicity trade-off contour has been constructed by fitting a curve to target values of pE (probability ofEfficacy) and pT (probability of Toxicity) of 0.30 and 0.40, respectively and probability cut-offs pE (for Efficacy)and pT (for Toxicity) set at 0.10 and 0.10,respectively.The area underneath the target contour has desirable πE, πT pairs. Up to 36 patients can be treated in cohorts of size 3. The 'best' dose is defined as that giving the largest response-toxicity trade-off.
- AE/SAE rate at completion of treatment [ Time Frame: After course 6. i.g. about 6 months ]
- Overall Rate Response [ Time Frame: After 2, 4 and 6 cycles ]
- Event Free Survival [ Time Frame: From the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason ]
- Time to Progression [ Time Frame: From entry until documented lymphoma progression or death as a result of lymphoma. ]
- Response Duration [ Time Frame: From the time when criteria for response (i.g. CR or PR) are met, for which the event is the first documentation of relapse or progression. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01412307
|Hematology Oncology and Stem Cell Transplantation Unit , IRCCS Fondazione "G.Pascale"|
|Naples, Italy, 80131|
|Principal Investigator:||Antonio Pinto, MD||Hematology Oncology and Stem Cell Transplantation Unit , IRCCS Fondazione "G.Pascale" - Naples, Italy|
|Principal Investigator:||Gaetano Corazzelli, MD||Hematology Oncology and Stem Cell Transplantation Unit , IRCCS Fondazione "G.Pascale" - Naples, Italy|